Sarepta Therapeutics Inc New (SRPT)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that...

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

– Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology...

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...

Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

DENVER, May 27, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology investors are entering one of the most catalyst-heavy clinical...